Jefferies Financial Group’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-17,400
Closed -$493K 1635
2025
Q1
$493K Buy
17,400
+5,400
+45% +$192K ﹤0.01% 1048
2024
Q4
$499K Buy
12,000
+10,800
+900% +$516K ﹤0.01% 1104
2024
Q3
$80.2K Sell
1,200
-19,300
-94% -$1.77M ﹤0.01% 1320
2024
Q2
$2.43M Sell
20,500
-18,200
-47% -$2.3M 0.03% 484
2024
Q1
$4.12M Buy
+38,700
New +$3.9M 0.04% 359

Other funds holding MRNA

Jefferies Financial Group's MRNA Position: Q1 2026 in Review

Jefferies Financial Group reduced its Moderna (MRNA) stake by 58% in Q1 2026, selling an estimated $1.24M and leaving 19,000 shares worth $965K. The position accounts for 0.01% of the portfolio, ranked #938.

Jefferies Financial Group first reported a position in MRNA in Q2 2023 and has held it in 12 quarters since. The position peaked at $47.3M in Q1 2024. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Jefferies Financial Group held 19,000 shares of Moderna worth $965K as of Q1 2026.
  • Jefferies Financial Group sold 26,670 Moderna shares in Q1 2026, an estimated $1.24M.
  • Moderna made up 0.01% of Jefferies Financial Group's portfolio in Q1 2026, its #938 holding.
  • Jefferies Financial Group first reported a position in Moderna in Q2 2023 and has held it in 12 quarters since.
  • Jefferies Financial Group's Moderna position peaked at $47.3M in Q1 2024.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.